| Symbol | BFRIW |
|---|---|
| Name | BIOFRONTERA INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 660 MAIN STREET, WOBURN, Massachusetts, 01801, United States |
| Telephone | +1 781 - 245-1325 |
| Fax | — |
| — | |
| Website | https://www.biofrontera-us.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | NASDAQ;OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Frankfurt Stock Exchange |
| CIK | 0001858685 |
| Description | Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. It also markets a topical antibiotic for the treatment of impetigo, a bacterial skin infection. Additional info from NASDAQ: Additional info from OTC: |
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
Read moreNew Form SCHEDULE 13G/A - Biofrontera Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001622627-26-000018 <b>Size:</b> 16 KB
Read moreDirector Luebbert Hermann 🟡 adjusted position in 0 shares (1 derivative) of Biofrontera Inc. (BFRI) Transaction Date: Jul 28, 2026 | Filing ID: 035273
Read moreLeffler Eugene Frederick 🟡 adjusted position in 0 shares (1 derivative) of Biofrontera Inc. (BFRI) Transaction Date: Jul 28, 2026 | Filing ID: 035271
Read moreNew Form S-8 - Biofrontera Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001493152-26-034268 <b>Size:</b> 438 KB
Read moreNew Form 10-K/A - Biofrontera Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001493152-26-034251 <b>Size:</b> 456 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07053852 | Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and… | Phase1 | Actinic Keratoses | Completed | 2025-06-27 | 2025-12-29 | ClinicalTrials.gov |
| NCT06577311 | Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous C… | Phase2 | Cutaneous Squamous Cell Carcinoma | Recruiting | 2024-08-14 | 2025-08-01 | ClinicalTrials.gov |
| NCT06027619 | Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynami… | Phase2 | Actinic Keratosis | Completed | 2023-10-02 | 2024-07-08 | ClinicalTrials.gov |
| NCT05662202 | Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®)… | Phase3 | Actinic Keratoses | Completed | 2022-12-12 | 2026-07-01 | ClinicalTrials.gov |
| NCT05080764 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoL… | Phase2 | Acne Vulgaris | Completed | 2021-12-10 | 2026-01-07 | ClinicalTrials.gov |
| NCT05060237 | Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodyna… | Phase1 | Actinic Keratosis | Completed | 2021-12-01 | 2023-04-20 | ClinicalTrials.gov |
| NCT04319159 | Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (… | Phase1 | Actinic Keratoses | Completed | 2020-03-05 | 2020-10-07 | ClinicalTrials.gov |
| NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoL… | Phase3 | Superficial Basal Cell Carcinoma | Active_Not_Recruiting | 2018-09-25 | 2029-02-01 | ClinicalTrials.gov |
| NCT02144077 | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcin… | Phase3 | Basal Cell Carcinoma (BCC) | Completed | 2014-01-28 | 2020-09-09 | ClinicalTrials.gov |
| NCT01966120 | Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis… | Phase3 | Actinic Keratosis | Completed | 2013-10-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02799069 | Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Ke… | Phase3 | Actinic Keratosis | Completed | 2008-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT02799082 | Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy … | Phase3 | Actinic Keratosis | Completed | 2007-12-01 | 2008-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Drug | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT05080764 |
| 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT) | Drug | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT05080764 |
| 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Drug | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT05080764 |
| 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT) | Drug | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT05080764 |
| Vehicle and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | COMPLETED | NCT05662202 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | COMPLETED | NCT05662202 |
| Vehicle and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| Vehicle and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| Vehicle and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| Vehicle and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| Vehicle and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| BF-200 ALA | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02799082 |
| Vehicle | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02799082 |
| Vehicle | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02799069 |
| MAL Cream | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02799069 |
| BF-200 ALA | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02799069 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE1 | Actinic Keratoses | COMPLETED | NCT04319159 |
| methyl-aminolevulinate | Other | Phase PHASE3 | Basal Cell Carcinoma (BCC) | COMPLETED | NCT02144077 |
| BF-200 ALA | Other | Phase PHASE3 | Basal Cell Carcinoma (BCC) | COMPLETED | NCT02144077 |
| Photodynamic therapy with BF-RhodoLED | Drug | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01966120 |
| Placebo to BF-200 ALA gel | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01966120 |
| BF-200 ALA gel | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01966120 |
| Aminolevulinic acid hydrochloride 10% topical gel with Red Light | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT06577311 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE1 | Actinic Keratosis | COMPLETED | NCT05060237 |
| Red light illumination | Other | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT06027619 |
| Topical aminolevulinate (10% ALA gel) | Other | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT06027619 |
| 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Drug | Phase PHASE2 | Acne Vulgaris | ACTIVE_NOT_RECRUITING | NCT05080764 |
| 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT) | Drug | Phase PHASE2 | Acne Vulgaris | ACTIVE_NOT_RECRUITING | NCT05080764 |
| 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Drug | Phase PHASE2 | Acne Vulgaris | ACTIVE_NOT_RECRUITING | NCT05080764 |
| 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT) | Drug | Phase PHASE2 | Acne Vulgaris | ACTIVE_NOT_RECRUITING | NCT05080764 |
| Sciton HEROic | Other | Phase PHASE1 | Actinic Keratoses | COMPLETED | NCT07053852 |
| Ameluz | Other | Phase PHASE1 | Actinic Keratoses | COMPLETED | NCT07053852 |
| Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Drug | Phase PHASE3 | Superficial Basal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03573401 |
| Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT) | Drug | Phase PHASE3 | Superficial Basal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03573401 |
| Vehicle and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| BF-200 ALA and red light LED lamp | Other | Phase PHASE3 | Actinic Keratoses | ACTIVE_NOT_RECRUITING | NCT05662202 |
| Red light illumination | DEVICE | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT06027619 |
| Topical aminolevulinate (10% ALA gel) | DRUG | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT06027619 |